Lotus Eye Hospital & Institute Ltd
₹ 72.5
0.35%
13 Dec
- close price
About
Incorporated in 1990, Lotus Eye Hospital
and Institute Ltd provides ophthalmology and other related services.[1]
Key Points
- Market Cap ₹ 151 Cr.
- Current Price ₹ 72.5
- High / Low ₹ 95.6 / 44.1
- Stock P/E 106
- Book Value ₹ 28.9
- Dividend Yield 0.00 %
- ROCE 7.07 %
- ROE 4.97 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 2.51 times its book value
- Promoter holding has decreased over last quarter: -1.16%
- The company has delivered a poor sales growth of 4.63% over past five years.
- Company has a low return on equity of 5.93% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
29.11 | 28.69 | 29.90 | 31.13 | 33.96 | 38.02 | 38.43 | 40.55 | 32.35 | 38.90 | 47.03 | 48.20 | 48.71 | |
25.51 | 25.40 | 27.72 | 27.14 | 30.63 | 33.68 | 35.21 | 36.57 | 28.73 | 32.98 | 39.35 | 41.57 | 43.56 | |
Operating Profit | 3.60 | 3.29 | 2.18 | 3.99 | 3.33 | 4.34 | 3.22 | 3.98 | 3.62 | 5.92 | 7.68 | 6.63 | 5.15 |
OPM % | 12.37% | 11.47% | 7.29% | 12.82% | 9.81% | 11.42% | 8.38% | 9.82% | 11.19% | 15.22% | 16.33% | 13.76% | 10.57% |
0.64 | 0.39 | 0.46 | 0.58 | 0.68 | 0.91 | 0.68 | 0.21 | 0.84 | 0.88 | 1.15 | 1.31 | 1.32 | |
Interest | 0.05 | 0.04 | 0.10 | 0.16 | 0.15 | 0.18 | 0.21 | 0.24 | 0.14 | 0.21 | 0.20 | 0.20 | 0.21 |
Depreciation | 3.73 | 3.54 | 4.76 | 4.44 | 3.44 | 3.37 | 3.06 | 2.50 | 2.33 | 2.50 | 2.98 | 3.73 | 4.39 |
Profit before tax | 0.46 | 0.10 | -2.22 | -0.03 | 0.42 | 1.70 | 0.63 | 1.45 | 1.99 | 4.09 | 5.65 | 4.01 | 1.87 |
Tax % | 8.70% | 60.00% | -10.81% | -400.00% | -7.14% | -2.35% | -12.70% | 26.90% | 21.11% | 27.14% | 27.79% | 27.43% | |
0.42 | 0.04 | -1.98 | 0.10 | 0.44 | 1.75 | 0.71 | 1.06 | 1.57 | 2.98 | 4.08 | 2.91 | 1.40 | |
EPS in Rs | 0.20 | 0.02 | -0.95 | 0.05 | 0.21 | 0.84 | 0.34 | 0.51 | 0.75 | 1.43 | 1.96 | 1.40 | 0.68 |
Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | 236.36% | 59.43% | -0.00% | -0.00% | 66.24% | 34.90% | 25.49% | -0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 5% |
3 Years: | 14% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 54% |
5 Years: | 33% |
3 Years: | 24% |
TTM: | -65% |
Stock Price CAGR | |
---|---|
10 Years: | 22% |
5 Years: | 26% |
3 Years: | 10% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 5% |
3 Years: | 6% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 |
Reserves | 30.53 | 30.57 | 28.59 | 28.69 | 29.26 | 29.84 | 29.32 | 30.46 | 31.90 | 33.81 | 36.78 | 38.61 | 39.31 |
0.26 | 0.18 | 0.83 | 0.66 | 0.48 | 0.29 | 0.22 | 0.32 | 0.40 | 1.24 | 0.67 | 1.11 | -0.00 | |
5.31 | 7.01 | 6.20 | 4.68 | 4.40 | 7.28 | 6.18 | 6.53 | 6.12 | 5.74 | 4.93 | 6.11 | 9.96 | |
Total Liabilities | 56.90 | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.59 | 63.18 | 66.63 | 70.07 |
45.31 | 46.94 | 47.04 | 43.57 | 41.32 | 42.52 | 44.14 | 42.67 | 40.54 | 44.07 | 44.18 | 48.65 | 52.84 | |
CWIP | 0.18 | 0.36 | 0.27 | 0.42 | 0.65 | 0.29 | 0.29 | -0.00 | -0.00 | -0.00 | -0.00 | 0.08 | -0.00 |
Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
11.41 | 11.26 | 9.11 | 10.84 | 12.97 | 15.40 | 12.09 | 15.44 | 18.68 | 17.52 | 19.00 | 17.90 | 17.23 | |
Total Assets | 56.90 | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.59 | 63.18 | 66.63 | 70.07 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3.71 | 4.41 | 2.37 | 3.38 | 2.97 | 5.78 | 4.20 | 4.97 | 2.73 | 4.39 | 4.39 | 5.68 | |
-1.20 | -5.05 | -4.65 | -0.85 | -1.06 | -3.86 | -4.01 | -0.68 | 0.49 | -3.92 | -2.19 | -4.63 | |
-0.16 | -0.77 | 1.87 | -0.58 | -0.25 | -1.51 | -1.41 | 0.13 | -0.32 | -1.58 | -1.71 | -3.40 | |
Net Cash Flow | 2.35 | -1.41 | -0.40 | 1.96 | 1.66 | 0.41 | -1.22 | 4.42 | 2.90 | -1.10 | 0.49 | -2.35 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 3.89 | 4.96 | 4.27 | 5.98 | 7.31 | 10.94 | 7.22 | 5.94 | 8.35 | 5.82 | 9.08 | 9.54 |
Inventory Days | 135.42 | 166.70 | 121.54 | 113.25 | 60.22 | 79.23 | 128.20 | 124.42 | 138.82 | 150.03 | 153.60 | 170.30 |
Days Payable | 160.79 | 130.52 | 125.08 | 105.51 | 87.32 | 129.95 | 167.37 | 170.41 | 220.72 | 207.18 | 173.42 | 183.56 |
Cash Conversion Cycle | -21.48 | 41.14 | 0.73 | 13.72 | -19.79 | -39.78 | -31.95 | -40.05 | -73.54 | -51.34 | -10.74 | -3.72 |
Working Capital Days | 0.25 | -13.10 | -19.90 | -8.56 | -8.92 | -26.02 | -14.53 | -21.33 | -20.99 | -10.98 | 12.34 | 8.86 |
ROCE % | 0.99% | 0.27% | -4.23% | 0.24% | 1.19% | 3.63% | 1.66% | 4.67% | 3.92% | 7.91% | 10.25% | 7.07% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Nov
-
Results For The Quarter Ended 30Th September 2024
12 Nov - Approved unaudited standalone results for Q2 FY2024.
-
Board Meeting Outcome for Outcome Of Board Meeting
12 Nov - Approved unaudited standalone results for Q2 FY2024.
-
Board Meeting Intimation for Consideration Of Unaudited Standalone Financial Results For The Half Year And Period Ended September 30Th 2024
4 Nov - Prior intimation of board meeting on financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Oct - Certificate under 74(5) of SEBI (DP) Regulations 2018 received from the RTA
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
LEHIL is a listed Corporate Eye Hospital providing value-added super specialty services from its 8 Centers in Tamil Nadu and Kerala